PR99416

TEL AVIV, Israel, Jan. 9, 2023 /PRNewswire=KYODO JBN/ --

The funds, provided by new investors and current shareholder, will be used to

support the Company clinical and regulatory path towards pre-market approval of

its TIVUS(TM) technology for the treatment of hypertension

SoniVie Ltd. ("SoniVie" or the "Company"), a medical device company developing

a proprietary solution to treat hypertension, announced today the completion of

a $60 million series C round financing. The financing was led by Andera

Partners, with participation from Supernova Invest and Omega Funds. Current

SoniVie shareholder TechWald also participated.

In conjunction with the financing, the Company appointed two renowned medtech

experts to its Board of Directors, Raymond W. Cohen and Zeev Zehavi, as

independent directors.

SoniVie has developed an ultrasound-based denervation technology with

application in multiple therapeutic areas. TIVUS(TM) (Therapeutic

Intra-Vascular Ultrasound System) employs high-frequency non-focused ultrasound

energy to ablate nerves in the renal artery to decrease blood pressure. This

minimally invasive investigational procedure can be used to treat patients

suffering from hypertension, which impacts millions of people worldwide and

substantially increases their risk of heart attack, stroke and kidney failure.

The proceeds from SoniVie financing are envisioned to be used to reach clinical

and regulatory milestones and to support TIVUS(TM) renal artery denervation

program.

Following this financing, the Board of Directors of the Company is chaired by

Zvika Slovin and composed of directors appointed by Andera Partners (Raphael

Wisniewski), Omega Funds (Claudio Nessi), Supernova Invest (Rémi Spagnol) and

TechWald Holding (Alessandro Piga), Sonivie CEO Tomaso Zambelli and independent

directors Raymond W. Cohen (CEO of Axonics) and Zeev Zehavi (former executive

JJDC).

"We are very pleased that this financing round concluded with such a resounding

success" said Tomaso Zambelli, CEO of SoniVie Ltd. "The new investors and the

Board of Directors bring significant experience to the Company in the field of

Renal Denervation for Hypertension".

Raphael Wisniewski of Andera Partners commented, "SoniVie TIVUS(TM) has the

potential to provide patients and physicians with a safe, efficient and easy to

use device. We are thrilled to support this talented management together with

our syndicate partners and our new board members".

About SoniVie

SoniVie is a medical device company developing TIVUS(TM), the only ultra-sound

denervation platform with active development programs in three therapeutic

areas: pulmonary artery denervation for pulmonary hypertension, renal artery

denervation for resistant hypertension, and lung denervation for chronic

obstructive pulmonary disease with chronic bronchitis. These diseases affect

millions of patients in the United States and Europe. SoniVie has operations in

Israel, US and Europe.

www.sonivie.com 

About Andera Partners

Created over 20 years ago, Andera Partners is a major player in private company

investments in France and internationally. Its teams manage over Euros 3.7

billion in investments in life sciences (Andera Life Sciences), growth and

buyout capital (Andera MidCap, Andera Expansion, Andera Croissance, Andera

Co-Invest), sponsorless transactions (Andera Acto) and ecological transition

(Andera Infra).

Andera Partners' mission is to work alongside companies and their managers to

support them in achieving strong and sustainable growth. The quality of

performance offered to our investors relies on a strong partnership between the

entrepreneurs in our portfolio companies and our teams, based on shared values.

Performance through collective engagement, the "Power of And", constitutes

Andera Partners' DNA.

Based in Paris, with offices in Antwerp, Milan and Munich, Andera Partners is

wholly owned by its teams, which count nearly 100 professionals, of which 60

investment professionals. It is structured as a partnership and managed by a

board of 12 partners. Responsible and committed, the management company

regularly forms partnerships with non-profit sector entities and takes concrete

action in the fight against global warming.

www.anderapartners.com 

About Supernova Invest

Supernova Invest is the leading deep tech Venture Capital firm in France,

managing Euros 400+ million AUM. The current portfolio includes 70+ impact

start-up companies that develop products and services leveraging breakthrough

technologies in 4 transition-centric sectors: Health, Energy & Environment,

Industry 4.0 and Digital Technology.

For 20 years, Supernova Invest has been providing long-term capital, operating

experience, and strategic support to back sustainable growth of tomorrow's deep

tech and industrial champions throughout the Venture Capital life cycle: seed,

early, late and growth stages. Supernova Invest also gathers the entire deep

tech value chain to support portfolio companies: industrials, corporate,

research centers and co-investors.

Supernova Invest is backed by the largest asset manager in Europe Amundi and by

the most innovative public research organization in Europe CEA.

supernovainvest.com [https://supernovainvest.com/en/]

About Omega Funds

Founded in 2004, Omega Funds is a leading international venture capital firm

that creates and invests in life sciences companies that target our world's

most urgent medical needs.

Omega focuses on identifying and supporting companies through value inflection

points across the full arc of innovation, from company formation through

clinical milestones and commercial adoption.

Omega Funds' portfolio companies have brought 48 products to market in multiple

therapeutic areas, including oncology, rare diseases, precision medicine and

others.

www.omegafunds.com [https://omegafunds.com/]

About TechWald

TechWald, a Group of Operational Holding Companies affiliated to TechWald

Holding S.p.A., is engaged in scouting and supporting high growth potential

early to development-stage companies committed to Healthcare Innovation.

TechWald and its international team of experienced healthcare executives have a

key strategic focus on the MedTech industry and intend to support the

development and the access to healthcare market of technologies and solutions

which can provide relevant sustainable clinical benefit and value for Patients,

Doctors and Healthcare Systems, rewarding Shareholders with a fair and ethical

profit.

Over the last year TechWald has been engaged as controlling shareholder of

SoniVie, providing financial and managerial support to the Company throughout

the initiation of the IDE approved Pilot trial and the completion of the series

C financing.

www.techwald.com [https://www.techwald.com/]

PR Contact:

Tomaso Zambelli

CEO, Sonivie

tomaso@sonivie.com

SOURCE: SoniVie